CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference

May 31, 2023

SAN MATEO, Calif., May 31, 2023 – CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City. CARGO is advancing an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies. The Company’s lead clinical candidate, CRG-022, is preparing to enter a pivotal Phase 2 clinical trial in 2023.

About CRG-022

CRG-022 is CARGO’s investigational cell therapy that is composed of autologous T-cells transduced with a lentiviral vector (m971-BBZ) expressing a CD22-targeting CAR. CD22 is a transmembrane protein expressed on normal B-cells and B-cell malignancies. Initial Phase 1 results with CARGO’s CD22 CAR T-cell therapy demonstrated durable complete responses in greater than 50% of patients with large B-cell lymphoma (LBCL) that is relapsed/refractory (R/R) to CD19 CAR T-cell therapy. CARGO believes that CRG-022, with its unique design, has the potential to safely and effectively treat LBCL, including patients for whom prior CD19 CAR T-cell therapies have failed.

About CARGO Therapeutics

Our mission is to outsmart cancer and develop the next generation of best-in-class CAR T-cell therapies. Our proprietary platform technologies enable us to engineer and develop next-generation best-in-class CAR T-cell therapies with the potential to achieve durable responses that are curative for more cancer patients. Our founders are pioneers and world experts in CAR T-cell therapy, and our team has experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at

CARGO is outsmarting cancer to deliver more cures.

Source: CARGO Therapeutics, Inc.

Find more information at

Follow us on LinkedIn: CARGO Therapeutics

Follow us on Twitter: @CARGOTx

Media Contact:

Maura Gavaghan